Contineum Therapeutics Ownership | Who Owns Contineum Therapeutics?

Contineum Therapeutics Ownership Summary

Contineum Therapeutics is owned by 110.30% institutional investors, 0.98% insiders. Suvretta capital management is the largest institutional shareholder, holding 10.26% of CTNM shares. Franklin Biotechnology Discv A(acc)USD is the top mutual fund, with 3.11% of its assets in Contineum Therapeutics shares.

CTNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Contineum Therapeutics	110.30%	0.98%	-11.28%
Sector	Healthcare Stocks	35.75%	11.89%	52.37%
Industry	Biotech Stocks	36.05%	11.82%	52.13%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Suvretta capital management	2.84M	10.26%	$37.11M
Janus henderson group	2.73M	9.87%	$35.59M
Johnson & johnson	1.98M	7.14%	$25.85M
Franklin resources	1.84M	6.64%	$24.02M
Balyasny asset management	1.69M	6.09%	$22.01M
Millennium management	1.54M	5.54%	$20.05M
Baker bros. advisors lp	1.42M	5.13%	$18.56M
Ra capital management	1.30M	4.68%	$16.93M
Perceptive advisors	1.26M	4.53%	$16.40M
Vanguard group	1.27M	4.52%	$14.53M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sectoral asset management	727.59K	7.87%	$9.50M
Red tree management	638.16K	7.45%	$8.33M
Versant venture management	542.63K	5.01%	$7.09M
Johnson & johnson	1.98M	3.96%	$25.85M
Great point partners	800.20K	2.40%	$10.45M
Verdad advisers, lp	86.03K	1.26%	$1.12M
Suvretta capital management	2.84M	0.95%	$37.11M
Ikarian capital	807.87K	0.86%	$10.55M
Boxer capital management	494.00K	0.85%	$6.45M
Hhlr advisors	669.34K	0.52%	$8.74M

Top Buyers

Holder	Shares	% Assets	Change
Millennium management	1.54M	0.01%	704.76K
Ikarian capital	807.87K	0.86%	525.00K
Citadel advisors	350.20K	0.00%	350.20K
Vanguard group	1.27M	0.00%	306.63K
Janus henderson group	2.73M	0.02%	285.86K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	1.30M	0.18%	-883.70K
Commodore capital lp	-	-	-816.33K
Point72 asset management	84.89K	0.00%	-674.34K
Saturn v capital management	-	-	-319.35K
Stempoint capital lp	-	-	-265.83K

New Positions

Holder	Shares	% Assets	Change	Value
Citadel advisors	350.20K	0.00%	350.20K	$4.57M
Vanguard fiduciary trust	153.92K	0.00%	153.92K	$2.01M
Verdad advisers, lp	86.03K	1.26%	86.03K	$1.12M
Dimensional fund advisors lp	59.95K	0.00%	59.95K	$782.10K
Wellington management group llp	55.61K	0.00%	55.61K	$726.25K

Sold Out

Holder	Change
Sbi securities	-1.00
Ifp advisors	-1.00
Srs capital advisors	-8.00
Cubist systematic strategies	-24.00
Golden state wealth management	-27.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	91	10.98%	30,555,242	3.22%	110	0.99%	51	-13.56%	21	133.33%
Dec 31, 2025	10	-83.87%	2,281,353	-86.95%	8	0.18%	7	-77.42%	1	-94.74%
Sep 30, 2025	12	-82.86%	2,288,931	-83.48%	8	0.31%	7	-82.93%	3	-85.71%
Jun 30, 2025	69	13.11%	13,845,129	2.06%	53	1.94%	40	42.86%	21	16.67%
Mar 31, 2025	62	5.08%	15,117,518	-3.45%	58	0.89%	27	-30.77%	18	100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Franklin Biotechnology Discv A(acc)USD	1.16M	3.11%	-
Vanguard Total Stock Mkt Idx Inv	910.66K	2.44%	-
Franklin Biotechnology Discovery A	676.12K	1.81%	-
Fidelity Select Health Care	450.00K	1.20%	-
Fidelity Advisor Health Care I	280.00K	0.75%	-
Vanguard Institutional Extnd Mkt Idx Tr	274.69K	0.73%	1.62K
iShares Biotechnology ETF	201.72K	0.54%	3.87K
Fidelity Extended Market Index	128.71K	0.34%	-470.00
Schwab US Small-Cap ETF™	115.50K	0.31%	72.00
Fidelity VIP Health Care Initial	80.00K	0.21%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 01, 2026	Lorrain Daniel S.	Chief Scientific Officer	Sell	$40.61K
Jun 30, 2026	Lorrain Daniel S.	Chief Scientific Officer	Sell	$462.29K
Jul 01, 2026	Lorrain Daniel S.	Chief Scientific Officer	Sell	$91.68K
Jun 30, 2026	Watkins Tim	CMO & Head of Development	Sell	$173.59K
Jun 30, 2026	Stengone Carmine N.	CEO and President	Sell	$160.08K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	2
2026 Q2	-	7
2026 Q1	-	15
2025 Q4	-	2
2025 Q2	-	-

CTNM Ownership FAQ

Who Owns Contineum Therapeutics?

Contineum Therapeutics shareholders are primarily institutional investors at 110.30%, followed by 0.98% insiders and -11.28% retail investors. The average institutional ownership in Contineum Therapeutics's industry, Biotech Stocks , is 36.05%, which Contineum Therapeutics exceeds.

Who owns the most shares of Contineum Therapeutics?

Contineum Therapeutics’s largest shareholders are Suvretta capital management (2.84M shares, 10.26%), Janus henderson group (2.73M shares, 9.87%), and Johnson & johnson (1.98M shares, 7.14%). Together, they hold 27.27% of Contineum Therapeutics’s total shares outstanding.

Does Blackrock own Contineum Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Contineum Therapeutics.

Who is Contineum Therapeutics’s biggest shareholder by percentage of total assets invested?

Sectoral asset management is Contineum Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.87% of its assets in 727.59K Contineum Therapeutics shares, valued at 9.5M$.

Who is the top mutual fund holder of Contineum Therapeutics shares?

Franklin Biotechnology Discv A(acc)USD is the top mutual fund holder of Contineum Therapeutics shares, with 3.11% of its total shares outstanding invested in 1.16M Contineum Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools